Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: -0.50 (-1.40%)
Spread: 0.50 (1.429%)
Open: 35.75
High: 35.75
Low: 35.25
Prev. Close: 35.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Call Option Agreement

21 Nov 2008 09:24

RNS Number : 6520I
China Real Estate Opportunities Ltd
21 November 2008
 

China Real Estate Opportunities Limited

 

CREO ANNOUNCES CALL OPTION IN RREEF CHINA COMMERICIAL TRUST

 

21 November 2008, Hong Kong - China Real Estate Opportunities Limited ("CREO" or the "Company"), an AIM listed property company with an established investment and development portfolio in China today announced that it had entered into a call option agreement to acquire a 25.65% stake or 119,043,500 units in RREEF China Commercial Trust ("RREEF CCT"), a Hong Kong-listed Real Estate Investment Trust ("REIT"), to be exercised on 12 January 2009 at a cost of HKD 387 million (£33.6 million). 

RREEF CCT listed on the Hong Kong Stock Exchange on 22 June 2007 and currently owns an international grade A office and retail complex in the Chaoyang District of Beijing. The property, Beijing Gateway Plaza, is a strongly performing commercial real estate asset of approximately 130,000 square metres, with occupancy of over 95%, and is entirely consistent with CREO's long-term investment and operating philosophy.

RREEF CCT is managed by RREEF China Reit Management Limited, which is owned by RREEF Alternative Investments through Deutsche Bank Asia Pacific.

As at June 2008, RREEF CCT had a net asset value (NAV) of HKD6.04 per share, whilst the individual asset had a gross property value of HKD8.56 per share (HKD3.99 billion, £347.0 million). An interim dividend of HKD18.63 cents per share was paid in June 2008. Based on the share price of HKD1.880 on 20 November 2008, RREEF CCT had a market capitalisation of HKD873 million (£75.9 million). 

CREO has secured the call option at HKD3.25 per share representing a 46% discount to NAV and 62% discount to gross property valueBased on the interim dividend outlined in the June 2008 interim accounts the exercise price of the call option of HKD3.25 equates to a dividend yield of 11.5% per annum.

Mr. Ray Horney, Chairman of China Real Estate Opportunities Limited said, "This transaction reinforces CREO's ongoing commitment to its core business and exhibits its capacity to identify strategic investments that maintain its position as one of the leading foreign investors in China's commercial real estate market and that are accretive to its existing investments".

-- Ends --

About CREO

CREO was listed on the AIM market in London on 11th July 2007 under ticker symbol CREO, having successfully raised £259 million. Harnessing the intimate local market knowledge and key relationships that Treasury Holdings has been able to develop through its presence in China since 2002, CREO's principal objective is to maximise capital growth from a portfolio of properties in China. The projects will all incorporate high quality design, specifications, and finishes synonymous with Treasury Holdings.

CREO, with an exclusive focus on the China real estate market currently owns seven high-quality, strategically located properties in ShanghaiBeijing, and Qingdao. The company's main focus is in the commercial real estate sector, with income-producing properties currently representing 75% of the total portfolio.

www.china-reo.com

www.treasuryholdings.com

For further information, please contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Treasury Holdings China 

Richard David, Managing Director

Tel: (+86) 21 6282 5000 

Davy

Des Carville

Tel: +353 1 679 6363

Media Enquiries:

Bankside Consultants

Simon Rothschild, Oliver Winters

Tel: + 44 (0)207 367 8888

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREAPFFADAPFEE
Date   Source Headline
23rd Dec 20217:00 amRNSExercise of Options
30th Nov 20217:00 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSExercise of Options
12th Nov 20217:00 amRNSAcquisition of Aber Electronics Limited
11th Nov 20217:00 amRNSAppointment of Joint Broker
30th Sep 202112:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSHalf-year Report
9th Sep 202111:23 amRNSDirector/PDMR Shareholding
8th Sep 20213:59 pmRNSHolding(s) in Company
16th Aug 20213:34 pmRNSOpen Offer Launch, Posting of Circular & GM Notice
13th Aug 20214:45 pmRNSResult of Placing
12th Aug 20215:37 pmRNSProposed Placing & Open Offer, Launch of ABB
30th Jul 20215:00 pmRNSTotal Voting Rights
20th Jul 20213:42 pmRNSShare Awards, Director Dealings & Issue of Equity
16th Jul 20217:00 amRNSOpening of United States East Coast Headquarters
1st Jul 20218:00 amRNSIssue of Equity
30th Jun 202110:30 amRNSResult of AGM
16th Jun 20217:00 amRNSMicroBlate Fine’s first in-human use update
14th Jun 20217:00 amRNSAcquisition of freehold site for £4.25m
4th Jun 20217:01 amRNSNotice of AGM
4th Jun 20217:00 amRNSFinal Results
26th May 20217:00 amRNSFurther health economics data validates technology
19th May 20217:00 amRNSTrading Update
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSExercise of Options
19th Feb 202111:31 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSTrading update
7th Jan 20217:00 amRNSUS FDA clearance for MicroBlate™ Flex device
9th Dec 202011:06 amRNSSecond Price Monitoring Extn
9th Dec 202011:00 amRNSPrice Monitoring Extension
9th Dec 20207:00 amRNSFirst clinical use of new Creo GI product
24th Nov 20201:36 pmRNSExercise of Options
3rd Nov 20207:00 amRNSAcquisition of Boucart Medical SRL
2nd Nov 20207:00 amRNSUS FDA clearance for MicroBlate™ Fine device
23rd Sep 20207:00 amRNSHalf-year Report
26th Aug 20204:09 pmRNSHolding(s) in Company
11th Aug 20207:00 amRNSExercise of Options
3rd Aug 20207:00 amRNSVideo abstract published endorsing Speedboat
24th Jul 202011:00 amRNSDirector/PDMR Shareholding
24th Jul 20207:00 amRNSAcquisition of Albyn Medical S.L.
13th Jul 202010:37 amRNSSecretary of State for Wales site visit
13th Jul 202010:08 amRNSSecretary of State for Wales site visit
6th Jul 20207:00 amRNSDirectorate Change
2nd Jul 20207:00 amRNSDevelopment loan for plasma sterilising product
24th Jun 202010:30 amRNSResult of AGM
15th Jun 20207:00 amRNSCE mark for five new devices
8th Jun 20207:00 amRNSIET Prize nomination
3rd Jun 20207:00 amRNSPositive NHS health economics data
27th May 20207:00 amRNSPosting of Annual Report & Notice of AGM
20th May 20207:00 amRNSCommercialisation Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.